Hangzhou Jianhai Technology, a China-based healthcare management software provider that counts artificial intelligence technology provider iFlytek as an investor, has raised RMB500m ($78.2m) in series B-plus funding, DealStreetAsia has reported.
Investment bank China Renaissance’s Huaxing Growth Capital subsidiary led the round, which was filled out by 3H Health Investment, Guoce Investment and Sequoia Capital China.
Founded in 2015, Jianhai has developed an artificial intelligence (AI) software platform that monitors patients once they leave hospital. It will use the funding to invest in intelligent disease management and improve its services.
Sequoia Capital China led Jianhai’s $23m series B round in March this year, investing alongside Source Code Capital and Sherpa Healthcare Partners, both of which had also invested in its $9m series A3 round in September 2020.
By July 2019, the company had reportedly raised roughly of $15m across three rounds, including “tens of millions” of yuan in a 2017 series A close and $4.5m in 2018. Its earlier investors include iFlytek’s corporate venturing unit, iFlytek Venture Capital, as well as SVB Capital and HaiBang Capital, according to DealStreetAsia.
